Akademik Veri Yönetim Sistemi
7th International Eurasian Conference on Biological and Chemical Sciences (EurasianBioChem 2024) , Ankara, Türkiye, 2 - 04 Ekim 2024, ss.126
Viral infections affect the
patient's life both acutely and chronically, and in acute cases, the patient's
quality of life is often permanently reduced. Favipiravir (FA) was first
approved against RNA viruses in Japan and was also used in the Sars-CoV-19
pandemic. FA targets RNA polymerase enzymes as a mechanism. In addition to
influenza, it is also used to treat diseases caused by other RNA viruses such
as Ebola, Arenavirus, Bunyavirus, Filovirus, West Nile Virus and Yellow Fever.
Considering the ease of obtaining it from the patient, using saliva instead of
plasma or serum to monitor changes in active substance concentrations may be a
new and easy option for drug level monitoring. Favipiravir dosing regimen varies
in different viral infections. Doses administered to achieve drug efficacy can
be at very high concentrations. The aim of the study is finding a new, easy
method that allow the separation and determination of FA in artificial saliva.
Artificial saliva was used to prepare solutions of FA at the desired
concentration values. FA extractions were performed by liquidliquid extraction
procedure. FA separation was performed by XBridge, C18 (100 x 4.6 mm, particle
size 5 mm)
analytical column and acetonitrile: phosphate buffer (50:50, v/v, pH=3.5, 20
mM) containing mobile phase at 1.2 mL/min. Detection of FA was performed by DAD
detector at 320 nm. The calibration curves were linear over the concentration
ranges of 0.5-3.0 mg/mL.
The recovery value was found 97.508 % (n=6) for 2.0 mg/mL. This method gives easy
separation techniques without any interference peaks and good resolution.
Consequently, this study describes a simple, sensitive, and practical HPLC-DAD
method which permits determination of FA in saliva. Keywords: Favipiravir,
HPLC-DAD, Artificial Saliva